MVA-EB-NA1-LMP2

Overview

MVA-EB-NA1-LMP2 (also referred to as MVA-EL in literature) is an investigational modified vaccinia Ankara (MVA) viral-vector therapeutic vaccine encoding EBV antigens EBNA1 and LMP2. It targets EBV latent proteins expressed in nasopharyngeal carcinoma (NPC) tumor cells.

Evidence in the corpus

• MVA-EB-NA1-LMP2 (MVA-EL) viral-vector EBV therapeutic vaccine listed among investigational EBV-targeted immunotherapy approaches for recurrent/metastatic NPC; EBV antigenic stability makes LMP1/LMP2/EBNA1 attractive vaccine and TCR-T targets PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.